These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3183683)

  • 1. Phase I study of 24-hour continuous intravenous infusion of recombinant human tumor necrosis factor.
    Steinmetz T; Schaadt M; Gähl R; Schenk V; Diehl V; Pfreundschuh M
    J Biol Response Mod; 1988 Oct; 7(5):417-23. PubMed ID: 3183683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of recombinant human tumor necrosis factor (rHu-TNF:PT-050).
    Taguchi T
    Cancer Detect Prev; 1988; 12(1-6):561-72. PubMed ID: 3180146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human pharmacological investigation of a human recombinant tumor necrosis factor preparation (PAC-4D) a phase-I trial.
    Lenk H; Tanneberger S; Müller U; Shiga T
    Arch Geschwulstforsch; 1988; 58(2):89-97. PubMed ID: 3377652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of recombinant human tumor necrosis factor in colorectal carcinoma.
    Schaadt M; Pfreundschuh M; Lorscheidt G; Peters KM; Steinmetz T; Diehl V
    J Biol Response Mod; 1990 Apr; 9(2):247-50. PubMed ID: 2341863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy.
    Hallahan DE; Vokes EE; Rubin SJ; O'Brien S; Samuels B; Vijaykumar S; Kufe DW; Phillips R; Weichselbaum RR
    Cancer J Sci Am; 1995; 1(3):204-9. PubMed ID: 9166477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
    Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
    Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local treatment of liver metastases with recombinant tumour necrosis factor (rTNF): a phase one study.
    IJzermans JN; van der Schelling GP; Scheringa M; Splinter TA; Marquet RL; Jeekel J
    Neth J Surg; 1991 Aug; 43(4):121-5. PubMed ID: 1944989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of recombinant tumor necrosis factor in cancer patients.
    Blick M; Sherwin SA; Rosenblum M; Gutterman J
    Cancer Res; 1987 Jun; 47(11):2986-9. PubMed ID: 3567916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
    Greenblatt MS; Mangalik A; Ferguson J; Elias L
    Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of recombinant human tumor necrosis factor-alpha in patients with advanced malignancies.
    Bartsch HH; Nagel GA; Mull R; Flener R; Pfizenmaier K
    Mol Biother; 1988; 1(1):21-9. PubMed ID: 3267369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of intravenous treatment with tumor necrosis factor alpha in patients with advanced cancer--phase I clinical trials].
    Muc M; Baranowski M
    Przegl Lek; 1995; 52(10):496-8. PubMed ID: 8834840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A phase I study of recombinant human tumor necrosis factor (rHu-TNF: PT-050). The PT-050 Study Group].
    Taguchi T
    Gan To Kagaku Ryoho; 1986 Dec; 13(12):3491-7. PubMed ID: 3024581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phase I clinical trial of intravenous recombinant human lymphotoxin-alpha derivative].
    Wang FH; Li YH; Li S; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):501-4. PubMed ID: 16613689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible biological indicators of the response to recombinant tumour necrosis factor alpha in patients with advanced neoplasms.
    Braczkowski R; Zubelewicz B; Romanowski W; Lissoni P; Brivio F
    J Exp Clin Cancer Res; 1998 Sep; 17(3):349-54. PubMed ID: 9894774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
    Robertson MJ; Mier JW; Logan T; Atkins M; Koon H; Koch KM; Kathman S; Pandite LN; Oei C; Kirby LC; Jewell RC; Bell WN; Thurmond LM; Weisenbach J; Roberts S; Dar MM
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4265-73. PubMed ID: 16857801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic administration of recombinant methionyl human interleukin-2 (Ala 125) to cancer patients: clinical results.
    Sarna GP; Figlin RA; Pertcheck M; Altrock B; Kradjian SA
    J Biol Response Mod; 1989 Feb; 8(1):16-24. PubMed ID: 2784163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease.
    Moritz T; Niederle N; Baumann J; May D; Kurschel E; Osieka R; Kempeni J; Schlick E; Schmidt CG
    Cancer Immunol Immunother; 1989; 29(2):144-50. PubMed ID: 2720707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
    Cunningham CC; Holmlund JT; Schiller JH; Geary RS; Kwoh TJ; Dorr A; Nemunaitis J
    Clin Cancer Res; 2000 May; 6(5):1626-31. PubMed ID: 10815879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2.
    Kolitz JE; Welte K; Wong GY; Holloway K; Merluzzi VJ; Engert A; Bradley EC; Konrad M; Polivka A; Gabrilove JL
    J Biol Response Mod; 1987 Aug; 6(4):412-29. PubMed ID: 3498011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.